Demaerschalk Bart M, Boyd Erica L, Barrett Kevin M, Gamble Dale M, Sonchik Sarah, Comer Meghan M, Wieser Judith, Hentz Joseph G, Fitz-Patrick Dennis, Chang Yu-Hui H
Department of Neurology, Mayo Clinic, Phoenix, AZ; Department of Neurology, Mayo Clinic, Jacksonville, FL; Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN; Center for Connected Care, Mayo Clinic, Rochester, MN.
Health Sciences Research, Mayo Clinic, Scottsdale, AZ.
J Stroke Cerebrovasc Dis. 2018 Nov;27(11):2940-2942. doi: 10.1016/j.jstrokecerebrovasdis.2018.06.024. Epub 2018 Aug 23.
To examine telemedicine as it applies to acute ischemic stroke care at a spoke hospital and the effect on patient outcomes, including the timeliness of response, quality of care, safety, morbidity, and mortality when compared to standard hub hospital stroke center care.
Retrospective review of prospectively entered quality/performance stroke/telestroke patient catalog data were completed for 1000 adult patients who presented with an acute ischemic stroke to the Mayo Clinic Hospitals (500 patients) or to one of thirteen Mayo Clinic affiliated telestroke spoke hospitals in the regions (500 patients). The primary outcome of interest was the percentage of accurate decision making for eligibility of IV alteplase administration assessed by blinded adjudication and the secondary outcomes pertained to complications, discharge parameters, and standard quality metrics.
There was no difference in the spoke hospital versus hub hospital groups in identifying and making the correct decision regarding which patients were eligible for IV alteplase administration (96% [95% confidence interval (CI): 94%-97%] versus 97% [95% CI: 95%-98%]; P = 0.32). There was no difference among the groups in proportion receiving IV alteplase, sustaining symptomatic intracranial hemorrhage, and mortality. Patients in the spoke group were less likely to have a favorable outcome at discharge, as defined by National Institutes of Health Stroke Scale (NIHSS): 0-1 or mRS: 0-1 or Glasgow Outcome Scale (GOS): 0-1 (21% versus, 35%; P < 0.001), were less likely to have venous thromboembolism prophylaxis (46% versus 63%; P < 0.01), were less likely to have received antithrombotic therapy (85% versus 90%; P = .02), were less likely to be discharged on anticoagulation when indicated (56% versus 64%; P = .01), and were less likely to be prescribed cholesterol reducing treatment (68% versus 72%; P < .001). The initial acute care hospital length of stay was longer for the spoke hospital group by one day (median: 4 versus 3; P < .001).
The key findings were that evidence-based stroke thrombolysis eligibility decision making, thrombolysis administration, and thrombolysis emergency stroke metrics were uniformly excellent for the spoke hospital group when compared to the standard hub hospital group. However, evidence-based stroke hospitalization and discharge metrics were inferior for the spoke hospital group when compared to the standard hub hospital.
研究远程医疗应用于基层医院急性缺血性卒中护理的情况,以及与标准的中心医院卒中中心护理相比,其对患者预后的影响,包括反应及时性、护理质量、安全性、发病率和死亡率。
对前瞻性录入的质量/绩效卒中/远程卒中患者目录数据进行回顾性分析,研究对象为1000例成年急性缺血性卒中患者,其中500例就诊于梅奥诊所医院,另外500例就诊于梅奥诊所在该地区的13家附属基层远程卒中医院之一。主要观察指标是通过盲法判定评估的静脉注射阿替普酶治疗 eligibility 的准确决策百分比,次要观察指标涉及并发症、出院参数和标准质量指标。
在确定哪些患者适合静脉注射阿替普酶并做出正确决策方面,基层医院组与中心医院组之间没有差异(96%[95%置信区间(CI):94%-97%]对97%[95%CI:95%-98%];P = 0.32)。两组在接受静脉注射阿替普酶、发生症状性颅内出血和死亡率方面没有差异。根据美国国立卫生研究院卒中量表(NIHSS)定义,基层医院组患者出院时获得良好预后的可能性较小:NIHSS评分0-1或改良Rankin量表(mRS)评分0-1或格拉斯哥预后量表(GOS)评分0-1(21%对35%;P < 0.001),接受静脉血栓栓塞预防的可能性较小(46%对63%;P < 0.01),接受抗血栓治疗的可能性较小(85%对90%;P = 0.02),在有指征时出院时接受抗凝治疗的可能性较小(56%对64%;P = 0.01),接受降胆固醇治疗的可能性较小(68%对72%;P < 0.001)。基层医院组的初始急性护理住院时间比中心医院组长一天(中位数:4天对3天;P < 0.001)。
关键发现是,与标准的中心医院组相比,基层医院组基于证据的卒中溶栓 eligibility 决策、溶栓给药和溶栓急诊卒中指标均同样出色。然而,与标准的中心医院相比,基层医院组基于证据的卒中住院和出院指标较差。